Plasma hemoglobin and the risk of death in HIV/AIDS patients treated with antiretroviral therapy

Aging (Albany NY). 2021 May 7;13(9):13061-13072. doi: 10.18632/aging.202987. Epub 2021 May 7.

Abstract

Background: Previous studies concerning the effect of plasma hemoglobin (HB) and other factors that may modify the risk of death in people living with HIV/AIDS (PLHIV) treated with antiretroviral therapy (ART) are limited.

Results: Higher HB was independently linked to a lower death risk in PLHIV, with a decrease of 29% (13%, 43%) per standard deviation (SD) increment after adjusting for CD4, VL and other potential factors [hazard ratio (HR): 0.71, 95% confidence interval (CI): 0.57-0.87, P<0.001]. In addition, the addition of HB to the predictive model containing VL and CD4 significantly improved the C-index, by 0.69% (95% CI: 0.68%-0.71%), and net discrimination, by 0.5% (95% CI: 0.0%-1.6%, P=0.040), when predicting the death risk of PLHIV.

Conclusions: A lower level of HB was an independent risk factor for HIV/AIDS-associated death in PLHIV. HB combined with VL and CD4 may be an appropriate predictive model of the death risk of PLHIV.

Materials and methods: A propensity-score matching (PSM) approach was applied to select a total of 750 PLHIV (150 deceased and 600 living) from the AIDS prevention and control information system in the Wenzhou area from 2006 to 2018. Multivariable Cox proportional hazards regression models were formulated to estimate the effect of HB. The predictive performance improvement contributed by HB was evaluated using the C-index and net reclassification improvement.

Keywords: C-index; HB; HIV/AIDS associated death; interaction; net discrimination.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acquired Immunodeficiency Syndrome / blood*
  • Acquired Immunodeficiency Syndrome / drug therapy*
  • Adult
  • Anti-Retroviral Agents / pharmacology*
  • Female
  • HIV Infections / drug therapy
  • HIV Infections / virology
  • Hemoglobins / metabolism*
  • Humans
  • Male
  • Proportional Hazards Models
  • Risk Factors

Substances

  • Anti-Retroviral Agents
  • Hemoglobins